DHODH-IN-23|cas:1346705-53-0|西域试剂

DHODH-IN-23,99.82%

产品编号：Bellancom-153112| CAS NO：1346705-53-0| 分子式：C₂₄H₂₁ClFNO₄| 分子量：441.88

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-153112	￥1000.00	杭州北京（现货）
Bellancom-153112	￥1600.00	杭州北京（现货）
Bellancom-153112	￥3500.00	杭州北京（现货）
Bellancom-153112	￥5500.00	杭州北京（现货）
Bellancom-153112	￥9500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

DHODH-IN-23

产品介绍

DHODH-IN-23 (Compound A) 是一种具有口服活性的 DHODH 抑制剂，可用于癌症的研究。

生物活性

DHODH-IN-23 (Compound A) is an orally active DHODH inhibitor that can be used for the research of cancer.

体外研究

DHODH-IN-23 (Compound A; 72 h) 抑制急性髓系白血病细胞增殖。
DHODH-IN-23 (0.1-3 μM; 72 h) 诱导 THP-1 细胞中 CDllb 的表达。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	U937, HL-60, THP-1, KG-1 and MV411
Concentration:
Incubation Time:	72 h
Result:	Inhibited cell growth with GI₅₀s of 2.4, 2.5, 2.5, 3.5 and 7.6 μM against U937, THP-1, MV411 HL-60 and KG-1, respectively.

RT-PCR

Cell Line:	THP-1 cells
Concentration:	72 h
Incubation Time:	0.1, 1 and 3 μM
Result:	Induced CDllb mRNA expression.

体内研究
(In Vivo)

DHODH-IN-23 (Compound A; 30 mg/kg; oral; twice daily for 21 days) 在 MV411 小鼠异种移植模型中显示出抗肿瘤活性。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MV411 mouse xenograft model
Dosage:	30 mg/kg
Administration:	Oral administration, twice daily for 21 days
Result:	Demonstrated significant anti-tumor activity both as a single agent and in combination with Cytarabine (HY-13605) at 20 mg/kg with tumor growth inhibitions of 37 and 73% respectively.

体内研究

DHODH-IN-23 (Compound A; 30 mg/kg; oral; twice daily for 21 days) 在 MV411 小鼠异种移植模型中显示出抗肿瘤活性。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MV411 mouse xenograft model
Dosage:	30 mg/kg
Administration:	Oral administration, twice daily for 21 days
Result:	Demonstrated significant anti-tumor activity both as a single agent and in combination with Cytarabine (HY-13605) at 20 mg/kg with tumor growth inhibitions of 37 and 73% respectively.

体内研究

DHODH-IN-23 (Compound A; 30 mg/kg; oral; twice daily for 21 days) 在 MV411 小鼠异种移植模型中显示出抗肿瘤活性。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MV411 mouse xenograft model
Dosage:	30 mg/kg
Administration:	Oral administration, twice daily for 21 days
Result:	Demonstrated significant anti-tumor activity both as a single agent and in combination with Cytarabine (HY-13605) at 20 mg/kg with tumor growth inhibitions of 37 and 73% respectively.

性状

Solid

溶解性数据

In Vitro:

DMSO : 125 mg/mL (282.88 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.2631 mL	11.3153 mL	22.6306 mL
5 mM	0.4526 mL	2.2631 mL	4.5261 mL
10 mM	0.2263 mL	1.1315 mL	2.2631 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式